Autism spectrum disorder phenotype in children with ambulatory cerebral palsy: A descriptive cross-sectional study / Sharon SMILE in Research in Autism Spectrum Disorders, 7-2 (February 2013)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 7-2 (February 2013) . - p.391-397 Titre : Autism spectrum disorder phenotype in children with ambulatory cerebral palsy: A descriptive cross-sectional study Type de document : texte imprimé Auteurs : Sharon SMILE, Auteur ; Annie DUPUIS, Auteur ; C. MACARTHUR, Auteur ; Wendy ROBERTS, Auteur ; D. FEHLINGS, Auteur Année de publication : 2013 Article en page(s) : p.391-397 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Cerebral palsy  Diagnosis  Co-morbidity Index. décimale : PER Périodiques Résumé : The current study aims to describe the cognitive profile, autism profile, medical and behavioral presentation of children with a dual diagnosis of cerebral palsy (CP) and autism spectrum disorder (ASD). Little is known about the dual presentation of CP and ASD. Timely diagnosis is imperative as early intervention may impact a child's developmental trajectory. The study used a cross-sectional descriptive design. We report data on cognitive profiles, ASD presenting symptoms, the time to definitive diagnosis of ASD, medical and behavioral co-morbidities in children with a dual diagnosis of CP and ASD. Seventy-two percent (72%) of children with CP + ASD had a developmental disability profile. Children were diagnosed with ASD at the median age of 66.5 months (range: 31'210 months). Repetitive behaviors were the most common ASD alerting symptom. Repetitive motor mannerisms were reported in 71% of CP + ASD population. Constipation, asthma and aggression showed highest statistical differences between CP + ASD group and CP only group. Our study has established that cognitive impairment is common amongst children with CP + ASD. ASD is diagnosed later in children with CP + ASD, than reference age of diagnosis in children with ASD. Medical and behavioral co-morbidities are common in children with CP + ASD. Clinicians need to be sensitized to the possibility of multiple diagnoses including ASD in children with cerebral palsy. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.10.008 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=186 [article] Autism spectrum disorder phenotype in children with ambulatory cerebral palsy: A descriptive cross-sectional study [texte imprimé] / Sharon SMILE, Auteur ; Annie DUPUIS, Auteur ; C. MACARTHUR, Auteur ; Wendy ROBERTS, Auteur ; D. FEHLINGS, Auteur . - 2013 . - p.391-397. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 7-2 (February 2013) . - p.391-397 Mots-clés : Autism spectrum disorder  Cerebral palsy  Diagnosis  Co-morbidity Index. décimale : PER Périodiques Résumé : The current study aims to describe the cognitive profile, autism profile, medical and behavioral presentation of children with a dual diagnosis of cerebral palsy (CP) and autism spectrum disorder (ASD). Little is known about the dual presentation of CP and ASD. Timely diagnosis is imperative as early intervention may impact a child's developmental trajectory. The study used a cross-sectional descriptive design. We report data on cognitive profiles, ASD presenting symptoms, the time to definitive diagnosis of ASD, medical and behavioral co-morbidities in children with a dual diagnosis of CP and ASD. Seventy-two percent (72%) of children with CP + ASD had a developmental disability profile. Children were diagnosed with ASD at the median age of 66.5 months (range: 31'210 months). Repetitive behaviors were the most common ASD alerting symptom. Repetitive motor mannerisms were reported in 71% of CP + ASD population. Constipation, asthma and aggression showed highest statistical differences between CP + ASD group and CP only group. Our study has established that cognitive impairment is common amongst children with CP + ASD. ASD is diagnosed later in children with CP + ASD, than reference age of diagnosis in children with ASD. Medical and behavioral co-morbidities are common in children with CP + ASD. Clinicians need to be sensitized to the possibility of multiple diagnoses including ASD in children with cerebral palsy. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.10.008 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=186

Pharmacotherapy in autism spectrum disorder / Sharon SMILE

Public ISBD in Clinician's Manual on Autism Spectrum Disorder / Evdokia ANAGNOSTOU Titre : Pharmacotherapy in autism spectrum disorder Type de document : texte imprimé Auteurs : Sharon SMILE, Auteur ; Evdokia ANAGNOSTOU, Auteur Année de publication : 2015 Importance : p.43-62 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=271 in Clinician's Manual on Autism Spectrum Disorder / Evdokia ANAGNOSTOU Pharmacotherapy in autism spectrum disorder [texte imprimé] / Sharon SMILE, Auteur ; Evdokia ANAGNOSTOU, Auteur . - 2015 . - p.43-62. Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=271

Exemplaires(0)

Disponibilité
aucun exemplaire

A pilot dose finding study of pioglitazone in autistic children / Lucia CAPANO in Molecular Autism, 9 (2018)  

Public ISBD [article]  inMolecular Autism > 9 (2018) . - 59p. Titre : A pilot dose finding study of pioglitazone in autistic children Type de document : texte imprimé Auteurs : Lucia CAPANO, Auteur ; Annie DUPUIS, Auteur ; Jessica BRIAN, Auteur ; Deepali MANKAD, Auteur ; Lisa GENORE, Auteur ; Rianne HASTIE ADAMS, Auteur ; Sharon SMILE, Auteur ; Toni LUI, Auteur ; Dina ODROBINA, Auteur ; Jane A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : 59p. Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Clinical trial  Cytokines  Drug therapy  Efficacy  Inflammation  Maximum tolerated dose (MTD)  Physiological effects of drugs  Pioglitazone  Safety profile  Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371 [article] A pilot dose finding study of pioglitazone in autistic children [texte imprimé] / Lucia CAPANO, Auteur ; Annie DUPUIS, Auteur ; Jessica BRIAN, Auteur ; Deepali MANKAD, Auteur ; Lisa GENORE, Auteur ; Rianne HASTIE ADAMS, Auteur ; Sharon SMILE, Auteur ; Toni LUI, Auteur ; Dina ODROBINA, Auteur ; Jane A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur . - 59p. Langues : Anglais (eng) in Molecular Autism > 9 (2018) . - 59p. Mots-clés : Autism spectrum disorder  Clinical trial  Cytokines  Drug therapy  Efficacy  Inflammation  Maximum tolerated dose (MTD)  Physiological effects of drugs  Pioglitazone  Safety profile  Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371

Prospective cohort study of vitamin D and autism spectrum disorder diagnoses in early childhood / Yamna ALI in Autism, 23-3 (April 2019)  

Public ISBD [article]  inAutism > 23-3 (April 2019) . - p.584-593 Titre : Prospective cohort study of vitamin D and autism spectrum disorder diagnoses in early childhood Type de document : texte imprimé Auteurs : Yamna ALI, Auteur ; Laura N. ANDERSON, Auteur ; Sharon SMILE, Auteur ; Yang CHEN, Auteur ; Cornelia M. BORKHOFF, Auteur ; Christine KOROSHEGYI, Auteur ; Gerald LEBOVIC, Auteur ; Patricia C. PARKIN, Auteur ; Catherine S. BIRKEN, Auteur ; Peter SZATMARI, Auteur ; Jonathon L. MAGUIRE, Auteur Article en page(s) : p.584-593 Langues : Anglais (eng) Mots-clés : 25-hydroxyvitamin D  autism spectrum disorder  early childhood  vitamin D Index. décimale : PER Périodiques Résumé : Several studies have suggested an association between vitamin D in childhood and autism spectrum disorder. No prospective studies have evaluated whether lower vitamin D levels precede ASD diagnoses – a necessary condition for causality. The objective of this study was to prospectively evaluate whether vitamin D serum levels in early childhood was associated with incident physician diagnosed ASD. A prospective cohort study was conducted using data from preschool-aged children in the TARGet Kids! practice-based research network in Toronto, Canada, from June 2008 to July 2015. 25-hydroxyvitamin D concentration was measured through blood samples and vitamin D supplementation from parent report. Autism spectrum disorder diagnosis was determined from medical records at follow-up visits. Covariates included age, sex, family history of autism spectrum disorder, maternal ethnicity, and neighborhood household income. Unadjusted and adjusted relative risks and 95% confidence intervals were estimated using Poisson regression with a robust error variance. In this study, 3852 children were included. Autism spectrum disorder diagnosis was identified in 41 children (incidence = 1.1%) over the observation period (average follow-up time = 2.5 years). An association between 25-hydroxyvitamin D concentration and autism spectrum disorder was not identified in the unadjusted (relative risk = 1.04, 95% confidence interval: 0.97, 1.11 per 10 nmol/L increase in 25-hydroxyvitamin D concentration) or adjusted models (adjusted relative risk = 1.06; 95% confidence interval: 0.95, 1.18). An association between vitamin D supplementation in early childhood and autism spectrum disorder was also not identified (adjusted relative risk = 0.86, 95% confidence interval: 0.46, 1.62). Vitamin D in early childhood may not be associated with incident physician diagnoses of autism spectrum disorder. En ligne : http://dx.doi.org/10.1177/1362361318756787 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=392 [article] Prospective cohort study of vitamin D and autism spectrum disorder diagnoses in early childhood [texte imprimé] / Yamna ALI, Auteur ; Laura N. ANDERSON, Auteur ; Sharon SMILE, Auteur ; Yang CHEN, Auteur ; Cornelia M. BORKHOFF, Auteur ; Christine KOROSHEGYI, Auteur ; Gerald LEBOVIC, Auteur ; Patricia C. PARKIN, Auteur ; Catherine S. BIRKEN, Auteur ; Peter SZATMARI, Auteur ; Jonathon L. MAGUIRE, Auteur . - p.584-593. Langues : Anglais (eng) in Autism > 23-3 (April 2019) . - p.584-593 Mots-clés : 25-hydroxyvitamin D  autism spectrum disorder  early childhood  vitamin D Index. décimale : PER Périodiques Résumé : Several studies have suggested an association between vitamin D in childhood and autism spectrum disorder. No prospective studies have evaluated whether lower vitamin D levels precede ASD diagnoses – a necessary condition for causality. The objective of this study was to prospectively evaluate whether vitamin D serum levels in early childhood was associated with incident physician diagnosed ASD. A prospective cohort study was conducted using data from preschool-aged children in the TARGet Kids! practice-based research network in Toronto, Canada, from June 2008 to July 2015. 25-hydroxyvitamin D concentration was measured through blood samples and vitamin D supplementation from parent report. Autism spectrum disorder diagnosis was determined from medical records at follow-up visits. Covariates included age, sex, family history of autism spectrum disorder, maternal ethnicity, and neighborhood household income. Unadjusted and adjusted relative risks and 95% confidence intervals were estimated using Poisson regression with a robust error variance. In this study, 3852 children were included. Autism spectrum disorder diagnosis was identified in 41 children (incidence = 1.1%) over the observation period (average follow-up time = 2.5 years). An association between 25-hydroxyvitamin D concentration and autism spectrum disorder was not identified in the unadjusted (relative risk = 1.04, 95% confidence interval: 0.97, 1.11 per 10 nmol/L increase in 25-hydroxyvitamin D concentration) or adjusted models (adjusted relative risk = 1.06; 95% confidence interval: 0.95, 1.18). An association between vitamin D supplementation in early childhood and autism spectrum disorder was also not identified (adjusted relative risk = 0.86, 95% confidence interval: 0.46, 1.62). Vitamin D in early childhood may not be associated with incident physician diagnoses of autism spectrum disorder. En ligne : http://dx.doi.org/10.1177/1362361318756787 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=392

A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism / Deepali MANKAD in Molecular Autism, (March 2015)  

Public ISBD [article]  inMolecular Autism > (March 2015) . - p.1-11 Titre : A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism Type de document : texte imprimé Auteurs : Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : p.1-11 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277 [article] A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism [texte imprimé] / Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur . - p.1-11. Langues : Anglais (eng) in Molecular Autism > (March 2015) . - p.1-11 Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277

---

1 (1 - 5 / 5) Par page : 25 50 100 200